Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration (Q50792115)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 November 2006

Language	Label	Description	Also known as
English	Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration	scientific article published on 10 November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

1

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

author name string

S Davis

2

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

J Brazier

3

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

publication date

10 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

21

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

12

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

1455-1463

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

Age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Adult vitelliform macular degeneration: a clinicopathological study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Utility values and age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

An introduction to Markov modelling for economic evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Multiattribute and single-attribute utility functions for the health utilities index mark 3 system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

What is the cost of blindness?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Handling uncertainty in cost-effectiveness models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

The Impact of Age-Related Macular Degeneration on Health Status Utility Values

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

21 January 2018

Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Two eyes are better than one: binocular enhancement in the contrast domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Binocular contrast inhibition in subjects with age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Binocular vision in older people with adventitious visual impairment: sometimes one eye is better than two

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702636

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.EYE.6702636

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/17086167

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50792115&oldid=2261472406"